Metabolic Burden Measured by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer

The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma

(2012) Silvia Park et al.   AMERICAN JOURNAL OF HEMATOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer

(2011) Dongyuan Zhu et al.   LUNG CANCER

Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer

(2010) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer

(2009) K. Hotta et al.   ANNALS OF ONCOLOGY

High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer

(2009) Y. J. Lee et al.   CLINICAL CANCER RESEARCH

Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project

(2009) Thierry Berghmans et al.   Journal of Thoracic Oncology

Prognostic Value of 18F-FDG Uptake on Positron Emission Tomography in Patients with Pathologic Stage I Non-small Cell Lung Cancer

(2009) Sang-Won Um et al.   Journal of Thoracic Oncology

Recommendations on the Use of 18F-FDG PET in Oncology

(2008) J. W. Fletcher et al.   JOURNAL OF NUCLEAR MEDICINE